1. Scrip
  2. >>Business

Roche Raises Outlook Despite US Biosimilars, Sees Spark Buy By Year-End

 
• By Sten Stovall

Roche presented a strong first-half performance and raised its outlook again for the full year as sales continued to be driven by its portfolio of new medicines. It said its delayed takeover of Spark Therapeutics should happen by year-end.

Growth
Roche looking beyond cancer drugs as newer medicines spur growth • Source: Shutterstock

A strong performance by recently-launched drugs in this year’s second quarter allowed Roche on 25 July to beat market forecasts and to raise its 2019 full-year outlook for the second time this year, boosted by management’s rising confidence that it can ride out a wave of biosimilars entering the US market in the second half and continue growing earnings into 2020.

Roche said second-quarter group sales grew 9% at constant exchange rates, with the pharma division revenue up 11%, driven mainly by Ocrevus (ocrelizumab), Perjeta (pertuzumab) and Tecentriq

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Business

A Short History Of MASH Deals, Culminating In GSK/Boston Pharma

 
• By Joseph Haas

Both high-profile failures and small investments that are yielding success so far characterize the dealmaking in MASH over the past 15 years or so.

BioMarin’s $270m Inozyme Buy Fits Right Into Enzyme Therapy Business

 
• By Mandy Jackson

BioMarin’s chief business officer James Sabry told Scrip that Inozyme’s enzyme replacement therapy INZ-701 aligns with the company’s existing portfolio and its areas of dealmaking focus.

Regeneron Wins PCSK9 Court Battle Against Amgen

 
• By Alaric DeArment

A federal court jury found Amgen liable for violating antitrust laws in allegedly preventing Praluent from competing against Repatha.

Novo Nordisk’s CEO Forced Out After Falling Behind In GLP-1 Battle

 
• By Andrew McConaghie

Company surprises investors with Jørgensen's exit but insists its strategy will not change.

More from Scrip

Novo Nordisk’s CEO Forced Out After Falling Behind In GLP-1 Battle

 
• By Andrew McConaghie

Company surprises investors with Jørgensen's exit but insists its strategy will not change.

In Brief: US FDA Delay Sends Biohaven Shares Down

 
• By Andrew McConaghie

The US regulator’s decision has taken Biohaven and investors by surprise, with the reason for a ‘major amendment’ status not clear.

Executives On The Move: Pathos Procures CEO From AstraZeneca, New CEO For TME Pharma, And More

Recent moves in the industry include changes at the top at Akamis Bio, Innospera Pharma & Ispen, plus Astellas Korea appoints an ex-Novartis Korea executive.